The epidemiology and treatment of gout

References

• RoddyEDohertyMEpidemiology of goutArthritis Res Therapy2010126223
   PubMed Web of Science ®Google Scholar
• McGillNWDieppePAThe role of serum and synovial fluid components in promotion of urate crystal formationJ Rheumatol1991187104210451717687
   PubMed Web of Science ®Google Scholar
• PopeRMTschoppJThe role of interleukin-1 and the inflammasome in gout. Implications for therapyArthritis Rheum200756103183318817907163
   PubMed Web of Science ®Google Scholar
• Popa-NitaOMaroisLParéGNaccachePHCrystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase TecArthritis Rheum20085861866187618512796
   PubMed Web of Science ®Google Scholar
• KlempPStansfieldSACastleBRobertsonMCGout is on the increase in New ZealandAnn Rheum Dis199756122269059136
   PubMed Web of Science ®Google Scholar
• WallaceKLRiedelAAJoseph-RidgeNWortmannRIncreasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care populationJ Rheumatol20043181582158715290739
   PubMed Web of Science ®Google Scholar
• WeaverALEpidemiology of goutCleve Clin J Med200875Suppl 5S9S1218819329
   PubMedGoogle Scholar
• MiaoZLiCChenYDietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern ChinaJ Rheumatol20083591859186418634142
   PubMed Web of Science ®Google Scholar
• ElliotAJCrossKWFlemingDMSeasonality and trends in the incidence and prevalence of gout in England and Wales 1994–2007Ann Rheum Dis200968111728173319029167
   PubMed Web of Science ®Google Scholar
• LawrenceRCHelmickCGArnettFCEstimates of the prevalence of arthritis and selected musculoskeletal disorders in the United StatesArthritis Rheum19984157787999588729
   PubMed Web of Science ®Google Scholar
• MikulsTRFarrarJTBilkerWBFernandesSSchumacherHRJrSaagKGGout epidemiology: results from the UK General Practice Research Database,1990–1999Ann Rheum Dis200564226727215647434
   PubMed Web of Science ®Google Scholar
• ChangSJKoYCWangTNChangFTCinkotaiFFChenCJHigh prevalence of gout and related risk factors in Taiwan’s AboriginesJ Rheumatol1997247136413699228138
   PubMed Web of Science ®Google Scholar
• CampionEWGlynnRJDeLabryLOAsymptomatic hyperuricemia. Risks and consequences in the Normative Aging StudyAm J Med19878234214263826098
   PubMedGoogle Scholar
• LinKCLinHYChouPThe interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective studyJ Rheumatol20002761501150510852278
   PubMed Web of Science ®Google Scholar
• HallAPBarryPEDawberTRMcNamaraPMEpidemiology of gout and hyperuricemia. A long-term population studyAm J Med196742127376016478
   PubMed Web of Science ®Google Scholar
• BrauerGWPriorIAA prospective study of gout in New Zealand MaorisAnn Rheum Dis1978375466472718280
   PubMed Web of Science ®Google Scholar
• ZimmetPZWhitehouseSJacksonLThomaKHigh prevalence of hyperuricaemia and gout in an urbanised Micronesian populationBr Med J19781612212371239647212
   PubMed Web of Science ®Google Scholar
• RoseBSPriorIADavidsonFGout and hyperuricaemia in New Zealand and PolynesiaExcerpta Med (Int Congreee Ser)1968148344353
   Google Scholar
• O’SullivanJBThe incidence of gout and related uric acid levels in Sudbury, MassachusettsExcerpta Med (Int Congreee Ser)1968148371376
   Google Scholar
• EmmersonBTNagelSLDuffyDLMartinNGGenetic control of the renal clearance of urate: a study of twinsAnn Rheum Dis19925133753771575585
   PubMed Web of Science ®Google Scholar
• van der HarstPBakkerSJde BoerRAReplication of the five novel loci for uric acid concentrations and potential mediating mechanismsHum Mol Genet201019238739519861489
   PubMed Web of Science ®Google Scholar
• GraesslerJGraesslerAUngerSAssociation of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian populationArthritis Rheum200654129230016385546
   PubMed Web of Science ®Google Scholar
• TaniguchiAUranoWYamanakaMA common mutation in an organic anion transporter gene, SLC22A12, is a suppressing factor for the development of goutArthritis Rheum20055282576257716059895
   PubMed Web of Science ®Google Scholar
• DehghanAKottgenAYangQAssociation of three genetic loci with uric acid concentration and risk of gout: a genome-wide association studyLancet200837296541953196118834626
   PubMed Web of Science ®Google Scholar
• VitartVRudanIHaywardCSLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and goutNat Genet200840443744218327257
   PubMed Web of Science ®Google Scholar
• ChoiHKAtkinsonKKarlsonEWCurhanGObesity, weight change, hypertension, diuretic use, and the risk of gout in men: the health professionals follow-up studyArch Intern Med2005165774274815824292
   PubMed Web of Science ®Google Scholar
• BholeVde VeraMRahmanMMKrishnanEChoiHEpidemiology of gout in women: Fifty-two-year followup of a prospective cohortArthritis Rheum20106241069107620131266
   PubMed Web of Science ®Google Scholar
• WilliamsPTEffects of diet, physical activity and performance, and body weight on incident gout in ostensibly healthy, vigorously active menAm J Clin Nutr20088751480148718469274
   PubMed Web of Science ®Google Scholar
• ChoiHKAtkinsonKKarlsonEWWillettWCurhanGAlcohol intake and risk of incident gout in men: a prospective studyLancet200436394171277128115094272
   PubMed Web of Science ®Google Scholar
• ChoiHKLiuSCurhanGIntake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination SurveyArthritis Rheum200552128328915641075
   PubMed Web of Science ®Google Scholar
• ChoiHKCurhanGSoft drinks, fructose consumption, and the risk of gout in men: prospective cohort studyBMJ2008336763930931218244959
   PubMed Web of Science ®Google Scholar
• UnderwoodMSugary drinks, fruit, and increased risk of gout. Dietary fructose could be a contributing factorBMJ2008336763928528618258933
   PubMed Web of Science ®Google Scholar
• ChoiHKGaoXCurhanGVitamin C intake and the risk of gout in men: a prospective studyArch Intern Med2009169550250719273781
   PubMedGoogle Scholar
• ChoiHKWillettWCurhanGCoffee consumption and risk of incident gout in men: a prospective studyArthritis Rheum20075662049205517530645
   PubMed Web of Science ®Google Scholar
• FamAGGout, diet and the insulin resistance syndromeJ Rheumatol20022971350135512136887
   PubMed Web of Science ®Google Scholar
• ChoiHKFordESPrevalence of the metabolic syndrome in individuals with hyperuricemiaAm J Med2007120544244717466656
   PubMed Web of Science ®Google Scholar
• ChoiHKFordESLiCPrevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination SurveyArthritis Rheum200757110911517266099
   PubMed Web of Science ®Google Scholar
• RodriguezGSorianoLCChoiHKImpact of diabetes against the future risk of developing goutAnn Rheum Dis201069122090209420570836
   PubMed Web of Science ®Google Scholar
• ChoiHKDe VeraMAKrishnanEGout and the risk of type 2 diabetes among men with a high cardiovascular risk profileRheumatology200847101567157018710901
   PubMed Web of Science ®Google Scholar
• CohenSDKimmelPLNeffRAgodoaLAbbottKCAssociation of incident gout and mortality in dialysis patientsJ Am Soc Nephrol200819112204221018508965
   PubMed Web of Science ®Google Scholar
• SteeleTHHyperuricemic nephropathiesNephron199981Suppl 145499873214
   PubMed Web of Science ®Google Scholar
• YuTSFBergerLDorphDJSmithHRenal function in gout. V. Factors influencing the renal haemodynamicsAm J Med1979675766771507087
   PubMed Web of Science ®Google Scholar
• GibsonTRodgersVPotterCSimmondsHAAllopurinol treatment and its effect on renal function in gout: a controlled studyAnn Rheum Dis198241159657039523
   PubMed Web of Science ®Google Scholar
• ChoiHKCurhanGIndependent impact of gout on mortality and risk for coronary heart diseaseCirculation2007116889490017698728
   PubMed Web of Science ®Google Scholar
• StrasakARuttmannEBrantLSerum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Austrian menClin Chemistry2008542273284
   Web of Science ®Google Scholar
• KuoCFSeeLCLuoSFGout: an independent risk factor for all-cause and cardiovascular mortalityRheumatology (Oxford)201049114114619933595
   PubMed Web of Science ®Google Scholar
• GaffoALEdwardsNLSaagKGGout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?Arthritis Res Ther200911424019725932
   PubMed Web of Science ®Google Scholar
• PascualEAnalysis of synovial fluid from healthy knees. Comparison with fluid from asymptomatic knees in RA, SLE and goutBr J Rheumatol199231Suppl 22191555036
   PubMedGoogle Scholar
• McGonagleDTanALShankaranarayanaSMaddenJEmeryPMcDermottMFManagement of treatment resistant inflammation of acute on chronic tophaceous gout with anakinraAnn Rheum Dis200766121683168417998217
   PubMed Web of Science ®Google Scholar
• DalbethNSmithTNicolsonBEnhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interaction with stromal cellsArthritis Rheum20085861854186518512794
   PubMed Web of Science ®Google Scholar
• MalikASchumacherHRDinnellaJEClayburneGMClinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysisJ Clin Rheumatol2009151222419125136
   PubMed Web of Science ®Google Scholar
• Von EssenRHölttäAMPikkarainenRQuality control of synovial fluid crystal identificationAnn Rheum Dis19985721071099613340
   PubMed Web of Science ®Google Scholar
• McGillNWYorkHFReproducibility of synovial fluid examination for crystalsAust N Z J Med19912157107131759919
   PubMedGoogle Scholar
• SchumacherHRSieckMSRothfussSReproducibility of synovial fluid analyses. A study among four laboratoriesArthritis Rheum19862967707743718565
   PubMed Web of Science ®Google Scholar
• HasselbacherPVariation in synovial fluid analysis by hospital laboratoriesArthritis Rheum19873066376423606682
   PubMed Web of Science ®Google Scholar
• McGillNWMcGillVGSynovial fluid examination for crystals. A 7 year continuous quality assurance programIntern Med J200636Suppl 2A28
   Google Scholar
• PascualEDohertyMAspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rateAnn Rheum Dis20096813718385278
   PubMed Web of Science ®Google Scholar
• SchlesingerNBakerDGSchumacherHRSerum uric acid during bouts of acute gouty arthritisJ Rheumatol19972411226522669375898
   PubMed Web of Science ®Google Scholar
• LoganJAMorrisonEMcGillPESerum uric acid in acute goutAnn Rheum Dis19975611696697
   PubMed Web of Science ®Google Scholar
• SchlesingerNOverview of the management of acute gout and the role of adrenocorticotrophic hormoneDrugs200868440741518318560
   PubMed Web of Science ®Google Scholar
• JanssensHJLucassenPLVan de LaarFAJanssenMVan de LisdonkEHSystemic corticosteroids for acute goutCochrane Database Syst Rev20082CD00552118425920
   PubMed Web of Science ®Google Scholar
• AhernMJMcCredieMReidCBrooksPMGordonTPJonesMDoes colchicine work? The results of the first controlled study in acute goutAust N Z J Med19871733013043314832
   PubMedGoogle Scholar
• NukiGColchicine: its mechanism of action and efficacy in crystal-induced inflammationCurr Rheumatol Rep200810321822718638431
   PubMedGoogle Scholar
• TerkeltaubRAFurstDEBennettKKookKACrockettRSDavisMWHigh versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicentre, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine studyArthritis Rheum20106241060106820131255
   PubMed Web of Science ®Google Scholar
• EleftheriouGBacisGFiocchiRSebastianoRColchicine-induced toxicity in a heart transplant patient with chronic renal failureClin Toxicol (Phila)200846982783018608282
   PubMed Web of Science ®Google Scholar
• Adverse Drug Reactions Advisory CommitteeFatal interactions and reactions with colchicine: beware CYP3A4 inhibitorsAust Adverse Drug Reactions Bull20082752
   Google Scholar
• BouquiéRDeslandesGRenaudCDaillyEHalounAJollietPColchicine-induced rhabdomyolysis in a heart/lung transplant patient with concurrent use of cyclosporine, pravastatin, and azithromycinJ Clin Rheumatol2011171283021169852
   PubMed Web of Science ®Google Scholar
• BurnsCMWortmannRLGout therapeutics: new drugs for an old diseaseLancet2011377976016517720719377
   PubMed Web of Science ®Google Scholar
• TauscheAKRichterKGrasslerAHanselSRochBSchroderHESevere gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic optionAnn Rheum Dis200463101351135215361402
   PubMed Web of Science ®Google Scholar
• Perez-RuizFLiotéFLowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?Arthritis Rheum20075771324132817907217
   PubMed Web of Science ®Google Scholar
• JordanKMCameronJSSnaithMBritish Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of goutRheumatology (Oxford)20074681372137417522099
   PubMed Web of Science ®Google Scholar
• ZhangWDohertyMBardinTEULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Ann Rheum Dis200665101312132416707532
   PubMed Web of Science ®Google Scholar
• SchumacherHRChenLXThe practical management of goutCleve Clin J Med200875Suppl 5S22S25
   PubMedGoogle Scholar
• SolomonDHAvornJLevinRBrookhartMAUric acid lowering therapy: prescribing patterns in a large cohort of older adultsAnn Rheum Dis200867560961317728328
   PubMed Web of Science ®Google Scholar
• BriesacherBAAndradeSEFouayziHChanKAComparison of drug adherence rates among patients with seven different medical conditionsPharmacotherapy200828443744318363527
   PubMed Web of Science ®Google Scholar
• ChungYLuCYGrahamGGMantADayROUtilization of allopurinol in the Australian communityIntern Med J200838638839518422564
   PubMed Web of Science ®Google Scholar
• ChaoJTerkeltaubRA critical reappraisal of allopurinol dosing, safety and efficacy for hyperuricemia in goutCurr Rheumatol Rep200911213514019296886
   PubMedGoogle Scholar
• YamanakaHTogashiRHakodaMOptimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatmentAdv Exp Med Biol199843113189598023
   PubMed Web of Science ®Google Scholar
• BorstadGCBryantLRAbelMPScroggieDAHarrisMDAllowayJAColchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritisJ Rheumatol200431122429243215570646
   PubMed Web of Science ®Google Scholar
• ReindersMKvan RoonENJansenTLEfficacy and tolerability of urate-lowering drugs in gout: a randomised trial of benzbromarone versus probenecid after failure of allopurinolAnn Rheum Dis2009681515618250112
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
   PubMed Web of Science ®Google Scholar
• ReindersMKHaagsmaCVan RoonENDose-escalation of allopurinol versus benzbromarone in gout patients: a randomised controlled trialEULAR CongressParis2009 OP–0157
   Google Scholar
• LeeMHGrahamGGWilliamsKMDayROA benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Drug Saf200831864366518636784
   PubMed Web of Science ®Google Scholar
• DalbethNStampLAllopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse eventsSemin Dial200720539139517897242
   PubMed Web of Science ®Google Scholar
• HandeKRNooneRMStoneWJSevere allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiencyAm J Med19847614756
   PubMed Web of Science ®Google Scholar
• DalbethNKumarSStampLGowPDose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with goutJ Rheumatol20063381646165016783857
   PubMed Web of Science ®Google Scholar
• PanomvanaDSripraditAngthararakSHigher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney diseaseJ Clin Rheumatol200814161118431090
   PubMed Web of Science ®Google Scholar
• LeeHYAriyasingheJTThirumoorthyTAllopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?Singapore Med J200849538438718465047
   PubMed Web of Science ®Google Scholar
• HalevySGhislainPDMockenhauptMAllopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJ Am Acad Dermatol2008581253217919772
   PubMed Web of Science ®Google Scholar
• Vazquez-MelladoJMoralesEMPacheco-TenaCBurgos-VargasRRelation between adverse events associated with allopurinol and renal function in patients with goutAnn Rheum Dis2001601098198311557658
   PubMed Web of Science ®Google Scholar
• SchumacherHRBeckerMALloydEMacDonaldPALademacherCFebuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety studyRheumatology (Oxford)200948218819419141576
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRWortmannRLFebuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutArthritis Rheum200552391692315751090
   PubMed Web of Science ®Google Scholar
• EdwardsNLFebuxostat: a new treatment for hyperuricaemia in goutIpsen sponsored symposium, EULAR CongressParis6132008
   Google Scholar
• Arthritis Drugs Advisory Committee MeetingDepartment of Health and Human Services, United States Food and Drug Administration Center for Drug Evaluation and Research11242008
   Google Scholar
• ChohanSSafety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactionsJ Rheumatol20113891957195921724706
   PubMed Web of Science ®Google Scholar
• OldfieldVPerryCMRasburicase: a review of its use in the management of anticancer therapy-induced hyperuricemiaDrugs200666452954516597166
   PubMed Web of Science ®Google Scholar
• RichettePBriereCHoenen-ClavertVLoeuilleDBardinTRasburicase for tophaceous gout not treatable with allopurinol: an exploratory studyJ Rheumatol200734102093209817896799
   PubMed Web of Science ®Google Scholar
• SundyJSBarafHSYoodRAEfficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trialsJAMA2011306771172021846852
   PubMed Web of Science ®Google Scholar